Turn Therapeutics Inc. (NASDAQ:TTRX) Stock Has Consensus Target Price of $9.00 According to Analysts

Shares of Turn Therapeutics Inc. (NASDAQ:TTRX) have been given a consensus recommendation of “Moderate Buy” by the six analysts that are currently covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation, one has issued a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $9.00.

Several research analysts have weighed in on TTRX shares. Lucid Cap Mkts upgraded Turn Therapeutics to a “strong-buy” rating in a research report on Thursday, September 24th. Zacks Research upgraded Turn Therapeutics to a “hold” rating in a research report on Tuesday, July 21st. WBB Securities restated a “sell” rating and issued a $10.00 price target on shares of Turn Therapeutics in a research report on Monday, September 14th. Weiss Ratings downgraded shares of Turn Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, August 18th. Finally, Wall Street Zen upgraded Turn Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, October 10th.

Turn Therapeutics Price Performance

Shares of TTRX stock opened at $11.59 on Friday. The firm has a 50 day moving average price of $11.60 and a two-hundred day moving average price of $7.88. The company has a debt-to-equity ratio of 8.83, a quick ratio of 1.19 and a current ratio of 1.19. Turn Therapeutics has a 12-month low of $2.57 and a 12-month high of $16.45.

Turn Therapeutics (NASDAQ:TTRX) last posted its earnings results on Wednesday, August 12th. The company reported ($0.20) EPS for the quarter. Research analysts predict that Turn Therapeutics will post -0.40 earnings per share for the current year.

Institutional Investors Weigh In On Turn Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the business. Tamar Securities LLC bought a new stake in Turn Therapeutics in the fourth quarter worth approximately $59,000. Bank of America Corp DE acquired a new position in Turn Therapeutics in the second quarter valued at approximately $103,000. Jefferies Financial Group Inc. bought a new position in shares of Turn Therapeutics during the 2nd quarter worth approximately $119,000. DDFG Inc boosted its holdings in shares of Turn Therapeutics by 34.9% during the 1st quarter. DDFG Inc now owns 70,534 shares of the company’s stock worth $226,000 after buying an additional 18,246 shares in the last quarter. Finally, Bridgewater Advisors Inc. bought a new position in shares of Turn Therapeutics during the 2nd quarter worth approximately $242,000.

Turn Therapeutics Company Profile

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events.